Follow
Kirsten Graeser
Kirsten Graeser
F. Hoffmann-La Roche Ltd.
Verified email at roche.com
Title
Cited by
Cited by
Year
Investigation of properties and recrystallisation behaviour of amorphous indomethacin samples prepared by different methods
P Karmwar, K Graeser, KC Gordon, CJ Strachan, T Rades
International journal of pharmaceutics 417 (1-2), 94-100, 2011
1702011
Correlating thermodynamic and kinetic parameters with amorphous stability
KA Graeser, JE Patterson, JA Zeitler, KC Gordon, T Rades
European journal of pharmaceutical sciences 37 (3-4), 492-498, 2009
1672009
Physicochemical properties and stability of two differently prepared amorphous forms of simvastatin
KA Graeser, CJ Strachan, JE Patterson, KC Gordon, T Rades
Crystal growth and design 8 (1), 128-135, 2008
1142008
The role of configurational entropy in amorphous systems
KA Graeser, JE Patterson, JA Zeitler, T Rades
Pharmaceutics 2 (2), 224-244, 2010
972010
Amorphous drugs and dosage forms
H Grohganz, K Löbmann, P Priemel, KT Jensen, K Graeser, C Strachan, ...
Journal of Drug Delivery Science and Technology 23 (4), 403-408, 2013
782013
Theoretical considerations in developing amorphous solid dispersions
R Laitinen, PA Priemel, S Surwase, K Graeser, CJ Strachan, H Grohganz, ...
Amorphous solid dispersions: theory and practice, 35-90, 2014
632014
Investigations on the effect of different cooling rates on the stability of amorphous indomethacin
P Karmwar, JP Boetker, KA Graeser, CJ Strachan, J Rantanen, T Rades
European journal of pharmaceutical sciences 44 (3), 341-350, 2011
592011
Effect of different preparation methods on the dissolution behaviour of amorphous indomethacin
P Karmwar, K Graeser, KC Gordon, CJ Strachan, T Rades
European journal of pharmaceutics and biopharmaceutics 80 (2), 459-464, 2012
562012
The ability of two in vitro lipolysis models reflecting the human and rat gastro-intestinal conditions to predict the in vivo performance of SNEDDS dosing regimens
SDS Jørgensen, M Al Sawaf, K Graeser, H Mu, A Müllertz, T Rades
European Journal of Pharmaceutics and Biopharmaceutics 124, 116-124, 2018
452018
Applying thermodynamic and kinetic parameters to predict the physical stability of two differently prepared amorphous forms of simvastatin
KA Graeser, JE Patterson, T Rades
Current drug delivery 6 (4), 374-382, 2009
352009
Measurement of amorphous indomethacin stability with NIR and Raman spectroscopy
JY Kao, CM McGoverin, KA Graeser, T Rades, KC Gordon
Vibrational Spectroscopy 58, 19-26, 2012
182012
Exploring the utility of the Chasing Principle: influence of drug-free SNEDDS composition on solubilization of carvedilol, cinnarizine and R3040 in aqueous suspension
SDS Jørgensen, T Rades, H Mu, K Graeser, A Müllertz
Acta pharmaceutica sinica B 9 (1), 194-201, 2019
172019
Molecular structure, properties, and states of matter
T Rades, KC Gordon, K Graeser
Remington: Essentials of Pharmaceutics; Pharmaceutical Press: London, UK …, 2013
152013
Development of stable liquid formulations for oligonucleotides
J Poecheim, KA Graeser, J Hoernschemeyer, G Becker, K Storch, M Printz
European Journal of Pharmaceutics and Biopharmaceutics 129, 80-87, 2018
122018
Physical stability of amorphous drugs: Evaluation of thermodynamic and kinetic parameters
KA Graeser, JE Patterson, T Rades
Journal of Pharmacy and Pharmacology 60, A46-A46, 2008
92008
Principles of controlled release
Y Perrie, T Rades, K Graeser
Drug Delivery: Fundamentals and Applications, 25-46, 2016
32016
Antisense oligonucleotides and their technical suitability to nebulization
LL Seidl, R Moog, KA Gräser
International Journal of Pharmaceutics, 124390, 2024
2024
Salts and crystalline forms of a taar1 agonist
KA Graeser, U Schwitter, F Stowasser, FNA Tixeront, R Trussardi
US Patent App. 17/946,743, 2023
2023
Salts and crystalline forms of a TAAR1 agonist
KA GRAESER, U Schwitter, F Stowasser, FNA TIXERONT, R Trussardi
AU Patent App. 2,021,238,632 A, 2022
2022
Salts and crystalline forms of a taar1 agonist
KA GRAESER, U Schwitter, F Stowasser, FNA TIXERONT, R Trussardi
2021
The system can't perform the operation now. Try again later.
Articles 1–20